Gut Enzyme ST8Sia6 Acts as a Molecular Brake on Intestinal Inflammation
Mice lacking the sialyltransferase ST8Sia6 develop spontaneous small bowel immune activation and heightened colitis susceptibility, revealing a new glycosylation-based immune checkpoint.
Summary
Researchers at Mayo Clinic discovered that the enzyme ST8Sia6, which adds sialic acid sugar modifications to immune cell proteins, is essential for preventing chronic gut inflammation. Mice without ST8Sia6 spontaneously accumulate activated immune cells in the small intestine, develop shortened bowels in adulthood, and suffer more severe colitis when chemically challenged. Loss of the enzyme amplifies pathogenic Th1 and Th17 T cell programs, boosts inflammatory chemokines CCL3, CCL4, and CCL5, and alters glycosylation of key immune regulators CD43 and CD45. Importantly, even partial loss of ST8Sia6 in heterozygous mice produced an intermediate inflammatory phenotype, suggesting that gut immune homeostasis is exquisitely sensitive to this enzyme's activity level.
Detailed Summary
Inflammatory bowel disease (IBD) affects millions globally, yet most of the 300+ genetic risk loci identified by genome-wide association studies remain poorly understood. This study, published in Cell Reports, focuses on one such candidate: ST8Sia6, a sialyltransferase that adds α2,8 di-sialic acid modifications to O-linked glycoproteins on immune cells. A SNP in ST8Sia6 was flagged in the Broad Institute IBD Exomes Browser with an odds ratio of 4.06 for Crohn's disease, motivating a deep functional investigation using knockout and heterozygous mouse models.
The researchers found that adult ST8Sia6-knockout (KO) mice spontaneously developed shortened small and large intestines compared to wild-type (WT) controls, with heterozygous mice showing an intermediate degree of shortening. Critically, this shortening was absent at weaning but emerged by adulthood, and histological scoring showed no overt pathology under steady-state conditions. Despite appearing outwardly healthy, KO mice harbored a 10- to 50-fold increase in CD45+ immune cells in the small bowel lamina propria and epithelium. No changes were observed in the colon, pointing to a small bowel-specific immune regulatory role for ST8Sia6.
Single-cell RNA sequencing of enriched CD45+ cells from the small bowel epithelium, small bowel lamina propria, and colon revealed multiple immune alterations unique to ST8Sia6-deficient animals. Notably, a novel population of CD8α⁻NK1.1⁺ Vγ4 γδ T cells expressing proinflammatory NK receptor genes (Klra1, Klrc1, Klre1) and IFN-γ appeared specifically in KO and heterozygous mice. Flow cytometry confirmed increased proportions of Th1 cells (T-bet+) and pathogenic Th17 cells (dual T-bet+RORγt+) in the small bowel lamina propria. These dual-positive pathogenic Th17 cells are well-established drivers of intestinal inflammation in human IBD.
Functionally, ST8Sia6-deficient T cells showed altered glycosylation of the immune modulators CD43 and CD45, detected using monoclonal antibodies specific to glycoforms. Upon in vitro stimulation, small bowel T cells from KO mice produced markedly elevated levels of TNF-α. ST8Sia6-deficient immune and epithelial cells also expressed elevated levels of the inflammatory chemokines CCL3, CCL4, and CCL5. TNF-α blockade alone was not sufficient to normalize gut homeostasis, suggesting the mechanism extends beyond this single cytokine pathway. Microbiome analyses (16S sequencing, cohousing experiments, antibiotic treatment) ruled out commensal bacteria as the primary driver of the phenotype.
When challenged with 2% dextran sodium sulfate (DSS), both KO and heterozygous mice showed significantly increased weight loss and reduced survival compared to WT mice, confirming that even partial loss of ST8Sia6 sensitizes the gut to inflammatory insult. The findings collectively establish ST8Sia6-mediated glycosylation as a previously unrecognized checkpoint controlling small bowel immune homeostasis, with direct implications for understanding IBD susceptibility loci and potentially developing glycosylation-targeted therapies.
Key Findings
- ST8Sia6-KO mice develop spontaneous small bowel immune cell accumulation (10–50× increase in CD45+ cells) without affecting the colon.
- Even heterozygous ST8Sia6 mice show an intermediate inflammatory phenotype, indicating dose-sensitive gut immune regulation.
- Loss of ST8Sia6 expands pathogenic dual T-bet+RORγt+ Th17 cells and a novel proinflammatory Vγ4 γδ T cell population in the small bowel.
- ST8Sia6 deficiency alters glycosylation of CD43 and CD45 on T cells and elevates chemokines CCL3, CCL4, and CCL5.
- Microbiome differences do not drive the phenotype; gut homeostasis defects persist after antibiotic treatment and cohousing.
Methodology
The study used ST8Sia6 knockout and heterozygous mouse models with steady-state immune phenotyping, DSS-induced colitis challenge, single-cell RNA sequencing of CD45-enriched intestinal cells, flow cytometry, IHC, FITC-dextran permeability assays, 16S microbiome sequencing, antibiotic depletion, and cohousing experiments. Glycoform-specific monoclonal antibodies were used to assess CD43 and CD45 modifications. All histological scoring was performed blinded by a board-certified veterinary pathologist.
Study Limitations
All experiments were conducted in mice, and direct validation in human IBD patient tissues or immune cells is lacking. The paper focuses on spontaneous steady-state phenotypes and DSS colitis, which may not fully recapitulate the complexity of human Crohn's disease or ulcerative colitis. The precise molecular mechanism by which altered CD43/CD45 glycosylation translates into pathogenic T cell activation remains to be fully elucidated.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: